Table 1 Baseline patient characteristics in Xuesaitong and placebo groups by age subgroups
Characteristic | No. (%) | |||||
|---|---|---|---|---|---|---|
 < 65 years (n = 1788) |  ≥ 65 years (n = 1178) | |||||
Xuesaitong group (n = 890) | Placebo group (n = 898) | P value | Xuesaitong group (n = 597) | Placebo group (n = 581) | P value | |
Age, median (IQR), y | 56 (51–61) | 56 (51–61) | 0.996 | 69 (67–72) | 69 (67–72) | 0.871 |
Sex | ||||||
 Male | 626 (70.34) | 675 (75.17) | 0.022 | 331 (55.44) | 350 (60.24) | 0.096 |
 Female | 264 (29.66) | 223 (24.83) |  | 266 (44.56) | 231 (39.76) |  |
BMIa, median (IQR), kg/m2 | 24.80 (22.90–27.00) | 24.80 (22.90–27.10) | 0.404 | 24.20 (22.35–26.10) | 24.00 (21.95–26.00) | 0.149 |
Blood pressure, median (IQR), mmHg | ||||||
 SBP | 143 (132–158) | 140 (130–156) | 0.150 | 141 (132–154) | 142 (134–158) | 0.063 |
 DBP | 88 (80–96) | 87 (80–96) | 0.914 | 81 (75–89) | 82 (77–90) | 0.038** |
Past medical history | ||||||
 Hypertension | 499 (56.07) | 502 (55.90) | 0.925 | 336 (56.28) | 319 (54.91) | 0.020** |
 Diabetes mellitus | 204 (22.92) | 214 (23.83) | 0.651 | 152 (25.46) | 147 (25.30) | 0.128 |
 Hyperlipidemia | 47 (5.28) | 51 (5.68) | 0.697 | 26 (4.36) | 28 (4.82) | 0.285 |
 Ischemic stroke | 118 (13.26) | 140 (15.59) | 0.328 | 99 (16.58) | 104 (17.90) | 0.534 |
 Transient ischemic attack | 2 (0.22) | 7 (0.78) | 0.246 | 1 (0.17) | 1 (0.17) | 0.477 |
Smoking status | ||||||
 Never smoking | 431 (48.43) | 425 (47.33) | 0.967 | 381 (63.82) | 352 (60.59) | 0.369 |
 Occasional smoking | 66 (7.42) | 74 (8.24) |  | 34 (5.70) | 33 (5.68) |  |
 Current smoking | 271 (30.45) | 278 (30.96) |  | 85 (14.24) | 107 (18.42) |  |
 Previous smoking | 81 (9.10) | 81 (9.02) |  | 73 (12.23) | 63 (10.84) |  |
 Unknown | 41 (4.61) | 40 (4.45) |  | 24 (4.02) | 26 (4.48) |  |
History of alcohol use | ||||||
 Never drinking | 474 (53.26) | 468 (52.12) | 0.555 | 399 (66.83) | 365 (62.82) | 0.340 |
 Occasional drinking | 192 (21.57) | 203 (22.61) |  | 87 (14.57) | 107 (18.42) |  |
 Current drinking | 137 (15.39) | 133 (14.81) |  | 54 (9.05) | 48 (8.26) |  |
 Previous drinking | 40 (4.49) | 54 (6.01) |  | 36 (6.03) | 34 (5.85) |  |
 Unknown | 47 (5.28) | 40 (4.45) |  | 21 (3.52) | 27 (4.65) |  |
TOAST classificationb | ||||||
 Large artery atherosclerosis | 471 (52.92) | 473 (52.67) | 0.800 | 318 (53.27) | 315 (54.22) | 0.817 |
 Cardioembolism | 10 (1.12) | 15 (1.67) |  | 5 (0.84) | 6 (1.03) |  |
 Small artery occlusion | 373 (41.91) | 373 (41.54) |  | 245 (41.04) | 238 (40.96) |  |
 Stroke of other determined etiology | 15 (1.69) | 12 (1.34) |  | 8 (1.34) | 4 (0.69) |  |
 Stroke of undetermined etiology | 21 (2.36) | 25 (2.78) |  | 21 (3.52) | 18 (3.10) |  |
History of oral Xuesaitong | ||||||
 Yes | 5 (0.56) | 14 (1.56) | 0.040** | 4 (0.67) | 10 (1.72) | 0.096 |
 No | 885 (99.44) | 884 (98.44) |  | 593 (99.33) | 571 (98.28) |  |
History of oral antiplatelet agents | ||||||
 Yes | 165 (18.54) | 166 (18.49) | 0.977 | 112 (18.76) | 109 (18.76) | 1.000 |
 No | 725 (81.46) | 732 (81.51) |  | 485 (81.24) | 472 (81.24) |  |
mRSc | ||||||
 mRS ≤ 1 | 282 (31.69) | 330 (36.75) | 0.075 | 218 (36.52) | 208 (35.80) | 0.716 |
 1 < mRS ≤ 2 | 193 (21.69) | 185 (20.60) |  | 114 (19.10) | 122 (21.00) |  |
 3 ≤ mRS ≤ 5 | 415 (46.63) | 383 (42.65) |  | 265 (44.39) | 251 (43.20) |  |
NIHSSd score, median (IQR) | 5 (4–7) | 5 (4–7) | 0.264 | 5 (4–7) | 5 (4–7) | 0.134 |
EQ- 5De score, median (IQR) | 75 (60–88) | 75 (60–89) | 0.764 | 70 (60–85) | 75 (60–90) | 0.458 |
BIf, median (IQR) | 75 (55–90) | 80 (55–90) | 0.053 | 75 (55–90) | 75 (55–90) | 0.602 |